The British rheumatoid outcome study group (BROSG) trial of symptomatic versus aggressive therapy in established rheumatoid arthritis

Submission date	Recruitment status	Prospectively registered		
25/04/2003	No longer recruiting	☐ Protocol		
Registration date	Overall study status	Statistical analysis plan		
25/04/2003	Completed	[X] Results		
Last Edited	Condition category	Individual participant data		
24/08/2009	Musculoskeletal Diseases			

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Prof Deborah Symmons

Contact details

ARC Epidemiology Research Unit University of Manchester Oxford Road Stopford Building Manchester United Kingdom M13 9PT +44 (0)161 275 5044 deborah@fs1.ser.man.ac.uk

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

HTA 94/45/02

Study information

Scientific Title

Acronym

BROSG

Study objectives

This multi-centre observer-blinded controlled trial will compare the outcome, in terms of disability, of two groups of 240 RA patients with 5-20 years disease duration. Group 1 will be managed predominantly in primary care with the goal of controlling joint pain and stiffness. Group 2 will be predominantly in the rheumatology clinic with the goal of controlling symptoms and suppressing clinical laboratory evidence of inflammation. Only Group 2 will be eligible to receive cytotoxic drugs and parenteral steroids. Both groups will attend an annual review clinic to be screened for the complications of RA. Algorithms will guide physicians in their choice of drugs. The study will include assessment of direct and indirect costs. The multi-professional project team will include clinicians, an epidemiologist, statistician, computer scientist and a health economist.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Multi-centre observer-blinded controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Screening

Participant information sheet

Health condition(s) or problem(s) studied

Rheumatoid arthritis

Interventions

Group 1 will be managed predominantly in primary care with the goal of controlling joint pain and stiffness. Group 2 will be predominantly in the rheumatology clinic with the goal of controlling symptoms and suppressing clinical laboratory evidence of inflammation. Only Group 2 will be eligible to receive cytotoxic drugs and parenteral steroids.

Intervention Type

Other

Phase

Not Specified

Primary outcome measure

Not provided at time of registration

Secondary outcome measures

Not provided at time of registration

Overall study start date

01/05/1997

Completion date

31/07/2002

Eligibility

Key inclusion criteria

Patients with rheumatoid arthritis of 5-20 years duration

Participant type(s)

Patient

Age group

Adult

Sex

Both

Target number of participants

480

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/05/1997

Date of final enrolment

31/07/2002

Locations

Countries of recruitment

England

United Kingdom

Study participating centre
ARC Epidemiology Research Unit
Manchester
United Kingdom
M13 9PT

Sponsor information

Organisation

Department of Health (UK)

Sponsor details

Quarry House Quarry Hill Leeds United Kingdom LS2 7UE +44 (0)1132 545 843 Sheila.Greener@doh.gsi.gov.uk

Sponsor type

Government

Website

http://www.dh.gov.uk/en/index.htm

ROR

https://ror.org/03sbpja79

Funder(s)

Funder type

Government

Funder Name

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/09/2005		Yes	No